{
}
Sartorius is poised for a recovery in 2025 after a challenging year, with expectations of profitable and moderate growth across both divisions. The company reported stable annual revenue of €3.38 billion and a strong fourth quarter, achieving €907 million in sales, a 6.5% increase year-over-year. Analysts have varied ratings, with JPMorgan maintaining an "Overweight" stance and a target price of €230, while UBS raised its target to €302 but kept a "Neutral" rating.
UBS has maintained a "Neutral" rating for Sartorius with a target price of 280 euros, following the company's strong fourth-quarter performance that surpassed expectations, particularly in order intake. Analyst Matthew Weston noted that the company's cautious outlook for 2025 is intentionally vague.
UBS has maintained a "Neutral" rating for Sartorius vz shares with a price target of 280 euros, following strong Q4 results that surpassed expectations, particularly in order intake. Despite a 12.3% rise in share price, there remains a slight downside potential of 0.36% against the target. The company’s Q4 2024 key figures are set to be released on January 28, 2025.
UBS AG has maintained a "Neutral" rating for Sartorius vz shares, setting a target price of 280 euros following strong fourth-quarter results that surpassed expectations, particularly in order intake. The share price rose by 12.3% to EUR 281.00, reflecting a 30.6% increase since the start of 2025. Key figures for Q4 2024 are set to be released on January 28, 2025.
UBS has upgraded its rating for Sartorius following the company's strong fourth-quarter performance, which surpassed expectations due to accelerated order intake. Analyst Matthew Weston noted that the company's cautious outlook for 2025 is intentionally conservative, reflecting qualitative statements for the upcoming year.
UBS has maintained a "Neutral" rating for Sartorius with a target price of 280 euros, following the company's strong fourth-quarter performance that surpassed expectations, particularly in order intake. Analyst Matthew Weston noted that the cautious outlook for 2025 appears to be a deliberate strategy.
UBS has maintained a "Neutral" rating for Sartorius with a target price of 280 euros following the company's strong fourth-quarter performance, which surpassed expectations due to accelerated order intake. Analyst Matthew Weston noted that the cautious outlook for 2025 is intentionally vague.
UBS has maintained a "Neutral" rating for Sartorius vz shares with a price target of €280, following a strong fourth quarter that exceeded expectations, particularly in order intake. The share price rose 12.2% to €280.80, reflecting a 30.5% gain since the start of 2025, despite a slight downside risk. The Q4 2024 financial results are set to be released on January 28, 2025.
UBS has maintained a "Neutral" rating for Sartorius with a price target of 280 euros, following strong fourth-quarter results that surpassed expectations, particularly in order intake. Analyst Matthew Weston noted that the company's cautious outlook for 2025 appears deliberate.
UBS has maintained a "Neutral" rating on Roche's non-voting equity securities, according to analyst Matthew Weston. The focus of the pharmaceutical company's upcoming annual results will be on the outlook for 2025.
Matthew Weston
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
sartorius reports strong fourth quarter and optimistic outlook for 2025
Euro
JPMorgan Chase & Co.
Warburg Research GmbH
Deutsche Bank RV Global PP
Sartorius AG
USA
DEU
CHE
Richard Vosser
Falko Friedrichs
Marion Schlegel
Michael Heider
Matthew Weston
James Vane-Tempest
Delphine Le Louet
Show more
07:28 29.01.2025
UBS maintains neutral rating on Sartorius amid cautious outlook for 2025
11:49 28.01.2025
ubs maintains neutral rating for sartorius with price target of 280 euros
11:28 28.01.2025
ubs maintains neutral rating on sartorius vz shares with target price of 280 euros
11:28 28.01.2025
ubs raises rating for sartorius after strong fourth quarter performance
10:49 28.01.2025
ubs maintains neutral rating on sartorius citing cautious outlook for 2025
10:49 28.01.2025
ubs maintains neutral rating for sartorius with target price of 280 euros
10:36 28.01.2025
ubs maintains neutral rating for sartorius vz shares with price target of 280 euros
10:28 28.01.2025
ubs maintains neutral rating on sartorius with cautious outlook for 2025
09:36 28.01.2025
ubs maintains neutral stance on roche ahead of annual results
22:49 27.01.2025
Trending
Subcategory
Corporate News
Industry Trends
Stock Market Updates
Retail and Consumer Goods
Global Financial Events
Finance Mergers & Acquisitions
Global Trade Developments
Industry Mergers & Acquisitions
Central Bank Actions
CEO Changes
Banking Regulations
Supply Chain Management
Startups & Entrepreneurship
Energy Sector Developments
Government Economic Policies
Workplace Trends
AI Innovations
Cryptocurrency Trends
Market Analysis and Predictions
Financial Scams and Security
Countries:
Companies:
The Goldman Sachs Group, Inc.
Bank of America Corporation
Apple Inc.
Alphabet Inc.
Barclays PLC
Tesla, Inc.
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank RV Global PP
Commerzbank AG
Lloyds Banking Group plc
PepsiCo, Inc.
BNP Paribas SA
Google Inc.
NVIDIA Corporation
UBS Group AG
Wix.com Ltd.
BP Castrol K.K.
Valvoline Inc.
Bosch Limited
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Indian Rupee
Japanese Yen
Indonesian Rupiah
Canadian Dollar
Russian Ruble
South Korean Won
United Arab Emirates Dirham
Offshore Chinese Yuan
Ghanaian Cedi
Hungarian Forint
Albanian Lek
Brazilian Real
Singapore Dollar
Qatari Riyal
Jordanian Dinar
People:
Donald Trump
Elon Musk
Warren Buffett
Sergey Brin
Larry Page
Goldman Sachs
Kelvin Taylor
Carsten Fritsch
Christopher Chandler
Scott Bessent
Martin Schlegel
Jerome Powell
Kubra Khan
Joe Biden
Volkmar Baur
Christopher Wallerstedt
Brian Moynihan
Airlangga Hartarto
Francesco Gaetano Caltagirone
Leonardo Del Vecchio